Bill Text: IL HR0014 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Urges the Illinois Department of Human Services to review the value of expanding its naloxone tool kit to include all U.S. Food and Drug Administration-approved versions of naloxone or other FDA-approved products to fight the Illinois opioid epidemic.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Passed) 2023-03-28 - Resolution Adopted [HR0014 Detail]

Download: Illinois-2023-HR0014-Introduced.html

---

HR0014 LRB103 25357 MST 51702 r
HOUSE RESOLUTION
WHEREAS, The Illinois Department of Public Health's May
2022 report recorded 3,013 fatalities that occurred in 2021
due to opioid overdoses; and
WHEREAS, The 3,013 Illinois opioid overdose deaths
represent a 2.3% increase from 2020 and a 35.8% spike from
2019; and
WHEREAS, In 2021, toxicology testing found that 2,672
(89%) of the opioid fatalities involved a synthetic opioid,
such as fentanyl; and
WHEREAS, A 4 milligram naloxone hydrochloride nasal spray
has been the principal tool used by bystanders and emergency
medical services (EMS) to revive an individual from an
overdose episode; and
WHEREAS, A study, published in the Harm Reduction Journal
in May 2022, surveyed 125 adult U.S. residents who had been
administered a 4 milligram naloxone nasal spray during an
opioid overdose and found that 78% used 2 or more doses and 30%
used 3 or more doses of naloxone; and
WHEREAS, A 2021 Johns Hopkins Bloomberg School of Public

HR0014 - 2 - LRB103 25357 MST 51702 r
Health study published in the Harm Reduction Journal reported
on a survey of 171 people who use opioids in suburban Maryland;
sixty-one (35.7%) of these people who use opioids had received
take-home naloxone over a six month period; 57% of naloxone
recipients used it to reverse an overdose; 79% of overdose
reversals reported needing more than 2 doses; and
WHEREAS, Published by the National Library of Medicine, a
study of the National Emergency Medical Services Information
System Database of more than 10,000 EMS agencies across 47
states with 946,000 calls giving naloxone shows that use of
naloxone multi-dosing by EMS increased 54% over five-years,
from 18.4% to 28.4% in 2020; and
WHEREAS, On April 30, 2021, the U.S. Food and Drug
Administration approved a higher 8 milligram dose of naloxone
hydrochloride nasal spray product to treat opioid overdose;
and
WHEREAS, On October 19, 2021, the U.S. Food and Drug
Administration also approved a single-dose, pre-filled syringe
that delivers 5 milligrams of naloxone hydrochloride solution
through intramuscular (in the muscle) or subcutaneous (under
the skin) injection; and
WHEREAS, Thirty-four U.S. states have open access to the 8

HR0014 - 3 - LRB103 25357 MST 51702 r
milligram naloxone nasal spray on their Naloxone Standing
Orders, including Ohio, Kentucky, Iowa, Pennsylvania,
Massachusetts, New Jersey, Virginia, Alabama, Florida,
Tennessee, Colorado, Alaska, New Hampshire, Illinois, Arizona,
Kansas, California, Texas, Georgia, South Carolina, North
Carolina, West Virginia, Michigan, Connecticut, Oklahoma,
Minnesota, Maine, Louisiana, Nevada, Idaho, Oregon, Nebraska,
and Vermont; and
WHEREAS, Thirteen state government agencies have purchased
the 8 milligram naloxone nasal spray, including Alabama,
Alaska, Colorado, Florida, Idaho, Iowa, Kentucky, New
Hampshire, Ohio, Pennsylvania, Tennessee, Wisconsin, and West
Virginia; and
WHEREAS, The U.S. Veterans Administration added the 8
milligram naloxone nasal spray to the National Formulary in
November 2021; and
WHEREAS, Seventy percent of the number of lives covered by
commercial insurance in the U.S. can access the 8 milligram
naloxone nasal spray; and
WHEREAS, Ninety percent of the number of lives covered by
Medicaid insurance in the U.S. (40 states) can access the 8
milligram naloxone nasal spray, including Illinois; and

HR0014 - 4 - LRB103 25357 MST 51702 r
WHEREAS, The current cost of the 4 milligram naloxone
nasal spray is $5.93 per milligram and the 8 milligram version
is $3.75 per milligram, or 36.7 percent less; and
WHEREAS, Being good stewards of taxpayer money is a
priority for the Illinois General Assembly; therefore, be it
RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
we strongly urge the Illinois Department of Human Services to
review the value of expanding its naloxone tool kit to include
all U.S. Food and Drug Administration-approved versions of
naloxone or other FDA-approved products to fight the Illinois
opioid epidemic; and be it further
RESOLVED, That suitable copies of this resolution be
delivered to the Governor of Illinois, the Governor's Chief
Behavioral Health Officer, the Secretary of the Department of
Human Services, and the Director of the Division of Substance
Use, Prevention and Recovery.